Effect of external application of traditional Chinese medicine combined with rituximab injection+CHOP chemotherapy on the short-term efficacy,IL-6,IL-8 and CEA in patients with non Hodgkin's lymphoma
Objective To explore the effect of external application of traditional Chinese medicine com-bined with rituximab injection+CHOP chemotherapy on the short-term efficacy,IL-6,IL-8 and CEA in patients with non Hodgkin's lymphoma.Methods A retrospective study was conducted on 118 patients with non Hodgkin's lymphoma admitted to Jiangnan Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine from June 2020 to March 2023.These patients were divided into a control group and an observation group based on their treatment regimens,with 59 patients in each group.The control group patients were treated with sequential chemotherapy with CHOP(cyclophosphamide+doxorubicin+vincristine+prednisone)regimen,while the observa-tion group patients were treated with a combination of traditional Chinese medicine external application combined with rituximab+CHOP chemotherapy regimen on the basis of the control group treatment regimen.The survival pe-riod,recent therapeutic effect,the levels of serum interleukin(IL-2,IL-6,IL-8),hepcidin(HEPC),carcinoembry-onic antigen(CEA)and lactate dehydrogenase(LDH)before and after at least four cycles of chemotherapy,distri-bution of T lymphocyte subsets,immunoglobulin expression levels,adverse reactions during chemotherapy,and quality of life were compared between the two groups.Results The two groups of patients achieved certain thera-peutic effects,with the objective response rate(ORR)and disease control rate(DCR)of 51％(30/59)and 64％(38/59)in the control group,respectively;The objective response rate and disease control rate of the observation group were 56％(33/59)and 78％(46/59),respectively.There was no statistically significant difference in the objective response rate between the two groups(P＞0.05),but the overall efficacy of the observation group was significantly better than that of the control group(P＜0.05).After one year of follow-up,the overall survival rate and progression free productivity of the observation group were significantly higher than those of the control group(P＜0.05).There was no significant statistical difference in various serum indicators between the two groups of patients before treat-ment(P＞0.05).After treatment,the levels of IL-2,IL-6,and IL-8 in the control group were(829±90)ng/L,(8.2± 1.7)ng/L,and(82±13)ng/L,respectively.And the levels of IL-2,IL-6,and IL-8 in the observation group were(905±94)ng/L,(6.2±1.3)ng/L,and(54±9)ng/L,respectively.After treatment,the levels of HEPC,CEA,and LDH in the control group were(38±4)ng/ml,(6.7±1.2)ng/ml,and(255±64)U/L,respectively.And the levels of HEPC,CEA,and LDH in the observation group were(30±4)ng/ml,(4.3±1.0)ng/ml,and(214±38)U/L,respectively.The CD3+,CD4+,and CD4+/CD8+values of the control group patients were(58±4),(26.6±3.0),and(1.24±0.32),respectively.And the CD3+,CD4+,and CD4+/CD8+values of the observation group patients were(62±5),(29.8±3.6),and(1.65± 0.35),respectively.The IgA,IgG,and IgM values of the control group patients were(1.89±0.56)ng/L,(12.8±2.6)ng/L,and(1.33±0.43)ng/L,respectively.The IgA,IgG,and IgM values of the observation group patients were(2.58± 0.44)ng/L,(15.8±3.3)ng/L,and(1.98±0.52)ng/L,respectively.The above differences were statistically significant(P＜0.05).No chemotherapy-related deaths occurred in either group.The main adverse effects were gastrointestinal symptoms,bone marrow suppression,and hair loss.The incidence of adverse reactions during treatment was 29％(17/59)in the control group and 34％(20/59)in the observation group,with no statistically significant difference(P＞0.05).The SF-36 scores of both groups of patients after treatment were significantly higher than before treatment(P＜0.05),and the observation group had significantly higher scores than the control group(P＜0.05).Conclusion The combination of traditional Chinese medicine external application,rituximab injection,and CHOP chemotherapy regimen has shown good short-term clinical efficacy in patients with non Hodgkin's lym-phoma.It can effectively improve the one-year survival rate and immune function of patients,improve their serum indicators,and control the side effects of treatment.
万方数据
维普
